― 206 ―7. Keats JJ, Maxwell CA, Taylor BJ, Hendzel MJ, Chesi M, Bergsagel PL, Larratt LM, Mant MJ, Reiman T, Belch AR, Pilarski LM. Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients. Blood, 105, 4060 (2005).8. Umehara T, Epidrugs: Toward Understanding and Treating Diverse Diseases. Epigenomes, 6, 18 (2022).9. Saito S, Kikuchi J, Koyama D, Sato S, Koyama H, Osada N, Kuroda Y, Akahane K, Inukai T, Umehara T, Furukawa Y. Eradication of central nervous system leukemia of T-cell origin with a brain-permeable LSD1 inhibitor. Clin Cancer Res, 25, 1601 (2019).10. Kikuchi J, Yamada S, Koyama D, Wada T, Nobuyoshi M, Izumi T, Akutsu M, Kano Y, Furukawa Y. The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases. J Biol Chem, 288, 25593 (2013).11. Kikuchi J, Hori M, Iha H, Toyama-Sorimachi N, Hagiwara S, Kuroda Y, Koyama D, Izumi T, Yasui H, Suzuki A, Furukawa Y. Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7. Leukemia, 34, 180 (2020).12. Kikuchi J, Koyama D, Mukai H, Furukawa Y. Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells. Int J Hematol, 99, 726 (2014).13. Osada N, Kikuchi J, Koyama D, Kuroda Y, Yasui H, Leverson JD, Furukawa Y. mTOR inhibitors sensitize multiple myeloma cells to venetoclax via IKZF3 and Blimp-1-mediated Bcl-2 up-regulation. Haematologica, 106, 3008 (2021).14. Hudlebusch HR, Santoni-Rugiu E, Simon R, Ralfkiær E, Rossing HH, Johansen JV, Jørgensen M, Sauter G, Helin K. The histone methyltransferase and putative oncoprotein MMSET is overexpressed in a large variety of human tumors. Clin Cancer Res, 17, 2919 (2011).15. Li N, Xue W, Yuan H, Dong B, Ding Y, Liu Y, Jiang M, Kan S, Sun T, Ren J, Pan Q, Li X, Zhang P, Hu G, Wang Y, Wang X, Li Q, Qin J. AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis. J Clin Invest, 127, 1284 (2017).
元のページ ../index.html#208